Next, we analyzed the relationships between METTL7B expression level and the clinicopathological characteristics of glioma patients, showing that the expression of METTL7B was significantly correlated with age, tumor stage, pathology, and IDH1mutation (p < 0.001), but not with gender or radiotherapy in glioma (p > 0.05) (Figure 2, Table 1, Supplementary Figure 1). This evidence concerns the gene TMT1B and central nervous system cancer.